1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Amgen Inc.
  6. News
  7. Summary
    AMGN   US0311621009

AMGEN INC.

(AMGN)
  Report
Real-time Estimate Cboe BZX  -  05/19 12:29:38 pm EDT
242.90 USD   -0.43%
05/18AMGEN INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/16AMGEN INC. : Ex-dividend day for
FA
05/13Avantor Names Jonathan Peacock Chairman
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

BridgeBio Pharma, Amgen Team Up to Evaluate Combination Treatment for Advanced Solid Tumors With Mutation

01/13/2022 | 08:02am EDT


© MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
AMGEN INC. -0.20% 243.48 Delayed Quote.8.44%
BRIDGEBIO PHARMA, INC. 5.92% 7.51 Delayed Quote.-57.49%
All news about AMGEN INC.
05/18AMGEN INC : Submission of Matters to a Vote of Security Holders (form 8-K)
AQ
05/16AMGEN INC. : Ex-dividend day for
FA
05/13Avantor Names Jonathan Peacock Chairman
MT
05/12Amgen and lance bass partner to encourage people to do a 'double take' to recognize the..
PR
05/12BridgeBio Inks BBP-398 License With Bristol Myers
DJ
05/11TRANSCRIPT : Amgen Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-202..
CI
05/11INSIDER SELL : Amgen
MT
05/10Pfizer to pay $11.6 bln for Biohaven to tap migraine market
RE
05/10Mizuho Securities Lifts Amgen's Price Target to $208 From $202, Citing Repatha Peak Rev..
MT
05/09Amgen announces webcast of 2022 bank of america healthcare conference
AQ
More news
Analyst Recommendations on AMGEN INC.
More recommendations
Financials (USD)
Sales 2022 26 205 M - -
Net income 2022 6 905 M - -
Net Debt 2022 26 803 M - -
P/E ratio 2022 19,2x
Yield 2022 3,11%
Capitalization 130 B 130 B -
EV / Sales 2022 6,00x
EV / Sales 2023 5,67x
Nbr of Employees 24 200
Free-Float 99,8%
Chart AMGEN INC.
Duration : Period :
Amgen Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AMGEN INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Last Close Price 243,96 $
Average target price 246,55 $
Spread / Average Target 1,06%
EPS Revisions
Managers and Directors
Robert A. Bradway Chairman, President & Chief Executive Officer
Peter H. Griffith Chief Financial Officer & Executive Vice President
David M. Reese Senior VP-Translational Sciences & Oncology
Darryl Sleep Chief Medical Officer & Senior VP-Global Medical
Mike Zahigian Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
AMGEN INC.8.44%130 323
JOHNSON & JOHNSON2.59%461 811
PFIZER, INC.-14.65%282 789
ABBVIE INC.12.58%269 361
ELI LILLY AND COMPANY6.87%265 718
ROCHE HOLDING AG-15.26%264 329